Pharmacovigilance: The risk-benefit balance of anti-amyloid antibodies for treatment of dementia

We have published a review in the British Journal of Clinical Pharmacology about the safety and effectiveness of anti-amyloid antibodies for the treatment of dementia. 

These products are truly innovative for unmet medical needs. The health burden of dementia is increasing exponentially worldwide. Everyone has been waiting for such products for decades.

However, the benefit/risk balance of these products and their place in real world clinical use are not yet fully understood and are evolving. 

The benefits observed in clinical trials need to be confirmed in real world clinical practice.  It remains to be seen how delicate patients with dementia will manage the complex requirements for using these products. They need  to have repeated infusions, genetic testing, a PET scan, repeated MRIs and regular clinical evaluation.  

The adverse reactions of these require to be monitored intensively to evaluate their severity, frequency and outcomes in real world use. 

Studying the  long term safety and effectiveness of these products can not be overemphasised. 

Best wishes
Saad